GMAB – Genmab A/S
Float Short %
0.58
Margin Of Safety %
-23
Put/Call OI Ratio
0.26
EPS Next Q Diff
-0.17
EPS Last/This Y
0.03
EPS This/Next Y
-0.09
Price
24.65
Target Price
31.54
Analyst Recom
1.78
Performance Q
17.21
Relative Volume
1.06
Beta
0.92
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | GMAB | 23.42 | 0.48 | 0.29 | 3447 |
| 2025-07-28 | GMAB | 23.09 | 0.48 | 0.00 | 3450 |
| 2025-07-29 | GMAB | 22.6 | 0.48 | 0.17 | 3453 |
| 2025-07-30 | GMAB | 22.27 | 0.48 | 0.00 | 3454 |
| 2025-07-31 | GMAB | 21.66 | 0.48 | 0.42 | 3460 |
| 2025-08-01 | GMAB | 21.77 | 0.48 | 0.07 | 3457 |
| 2025-08-04 | GMAB | 21.98 | 0.48 | 0.00 | 3469 |
| 2025-08-05 | GMAB | 22.11 | 0.49 | 0.00 | 3418 |
| 2025-08-06 | GMAB | 21.54 | 0.48 | 1.00 | 3441 |
| 2025-08-07 | GMAB | 22.7 | 0.48 | 0.08 | 3459 |
| 2025-08-08 | GMAB | 21.44 | 0.48 | 0.33 | 3551 |
| 2025-08-11 | GMAB | 21.08 | 0.48 | 12.38 | 3555 |
| 2025-08-12 | GMAB | 21.88 | 0.39 | 0.00 | 3363 |
| 2025-08-13 | GMAB | 22.71 | 0.36 | 0.04 | 3545 |
| 2025-08-14 | GMAB | 23 | 0.36 | 0.05 | 3536 |
| 2025-08-15 | GMAB | 23.3 | 0.36 | 0.08 | 3569 |
| 2025-08-18 | GMAB | 23.42 | 0.25 | 0.67 | 1453 |
| 2025-08-19 | GMAB | 23.82 | 0.27 | 0.01 | 1485 |
| 2025-08-20 | GMAB | 24.08 | 0.21 | 0.53 | 1814 |
| 2025-08-21 | GMAB | 24.42 | 0.22 | 0.08 | 1825 |
| 2025-08-22 | GMAB | 24.65 | 0.26 | 0.26 | 1720 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | GMAB | 23.40 | 5.9 | 104.5 | 1.34 |
| 2025-07-28 | GMAB | 23.12 | 5.9 | 34.6 | 1.34 |
| 2025-07-29 | GMAB | 22.60 | 5.9 | -11.1 | 1.34 |
| 2025-07-30 | GMAB | 22.27 | 5.9 | 3.2 | 1.34 |
| 2025-07-31 | GMAB | 21.67 | 5.9 | -36.6 | 1.34 |
| 2025-08-01 | GMAB | 21.78 | 5.9 | -28.3 | 1.34 |
| 2025-08-04 | GMAB | 21.98 | 5.9 | 83.5 | 1.34 |
| 2025-08-05 | GMAB | 22.10 | 5.9 | 76.1 | 1.34 |
| 2025-08-06 | GMAB | 21.53 | 5.9 | -59.3 | 1.34 |
| 2025-08-07 | GMAB | 22.69 | 5.9 | 95.8 | 1.34 |
| 2025-08-08 | GMAB | 21.43 | 5.9 | -85.9 | 1.34 |
| 2025-08-11 | GMAB | 21.09 | 5.9 | -27.2 | 1.34 |
| 2025-08-12 | GMAB | 21.88 | 53.2 | 71.8 | 1.75 |
| 2025-08-13 | GMAB | 22.67 | 53.2 | -610.5 | 1.75 |
| 2025-08-14 | GMAB | 23.00 | 53.2 | -651.0 | 1.75 |
| 2025-08-15 | GMAB | 23.31 | 53.2 | -689.1 | 1.75 |
| 2025-08-18 | GMAB | 23.42 | 53.2 | -707.3 | 1.75 |
| 2025-08-19 | GMAB | 23.82 | 53.2 | -698.9 | 1.75 |
| 2025-08-20 | GMAB | 24.07 | 53.2 | -693.7 | 1.75 |
| 2025-08-21 | GMAB | 24.42 | 53.2 | -696.7 | 1.73 |
| 2025-08-22 | GMAB | 24.65 | 53.2 | -705.8 | 1.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | GMAB | 0 | -0.29 | 0.60 |
| 2025-07-28 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-29 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-30 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-31 | GMAB | 0 | -0.37 | 0.60 |
| 2025-08-01 | GMAB | 0 | -0.37 | 0.60 |
| 2025-08-04 | GMAB | 0 | -0.41 | 0.60 |
| 2025-08-05 | GMAB | 0 | -0.41 | 0.60 |
| 2025-08-06 | GMAB | 0 | -0.41 | 0.60 |
| 2025-08-07 | GMAB | 0 | -0.41 | 0.60 |
| 2025-08-08 | GMAB | 0 | -0.41 | 0.60 |
| 2025-08-11 | GMAB | 0 | -0.45 | 0.60 |
| 2025-08-12 | GMAB | 0 | -0.45 | 0.58 |
| 2025-08-13 | GMAB | 0 | -0.45 | 0.58 |
| 2025-08-14 | GMAB | 0 | -0.45 | 0.58 |
| 2025-08-15 | GMAB | 0 | -0.45 | 0.58 |
| 2025-08-18 | GMAB | 0 | -0.41 | 0 |
| 2025-08-19 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-20 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-21 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-22 | GMAB | 0 | -0.41 | 0.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.54
Avg. EPS Est. Current Quarter
0.44
Avg. EPS Est. Next Quarter
0.37
Insider Transactions
Institutional Transactions
-0.41
Beta
0.92
Average Sales Estimate Current Quarter
6205
Average Sales Estimate Next Quarter
6473
Fair Value
18.93
Quality Score
100
Growth Score
92
Sentiment Score
75
Actual DrawDown %
49.8
Max Drawdown 5-Year %
-63.1
Target Price
31.54
P/E
12.31
Forward P/E
12.89
PEG
1.05
P/S
4.47
P/B
2.86
P/Free Cash Flow
15.08
EPS
2
Average EPS Est. Cur. Y
1.73
EPS Next Y. (Est.)
1.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
37.52
Relative Volume
1.06
Return on Equity vs Sector %
-1.5
Return on Equity vs Industry %
11.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.39
EBIT Estimation
-705.8
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2639
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading